Table 2.

Chemotherapy regimens of studies included in the meta-analysis

Author, year	Chemotherapy regimens
Fotopoulou et al., 2008 [27]	Platinum/paclitaxel-based chemotherapy.
Fotopoulou et al., 2009 [14]	Platinum-based first-line chemotherapy.
Mereu et al., 2009 [28]	The first-line chemotherapy schedules were as follows: cysplatinum (CDDP 50 mg/mq weekly), cysplatinum + other drugs (CDDP 50 mg/mq + cyclophosphamide 600 mg/mq T adriamycin 45 mg/mq every 3Y4 weeks), carboplatin (JM8 AUC6 every 3Y4 weeks), and carboplatin + other drugs (JM8 AUC6 + paclitaxel 175Y225 mg/mq every 3 weeks, JM8 AUC6 + epirubicin 120 mg/mq every 4 weeks, JM8 AUC5 + paclitaxel 175 mg/mq + topotecam 1 mg/mq per 3 days every 3 weeks).
Guardiola et al., 2010 [29]	Chemotherapy with platinum-containing regimens.
Saadeh et al., 2013 [30]	Adjuvant and neoadjuvant chemotherapy (details were unavailable).
Pant et al., 2014 [31]	Frontline adjuvant chemotherapy (details were unavailable).
Chavan et al., 2017 [15]	Adjuvant and neoadjuvant chemotherapy (details were unavailable).
Greco et al., 2017 [32]	Neoadjuvant chemotherapy (details were unavailable).
Kuk et al., 2017 [33]	The control group (26 patients) was treated with three to six cycles of standard first-line chemotherapy consisting of carboplatin (AUC 6 i.v.) and paclitaxel (175 mg/m2 i.v.) (CP). The study group (31 patients) was treated with CP chemotherapy with the addition of bevacizumab (7.5 mg/kg bw i.v.).
Zhang et al., 2018 [16]	Neoadjuvant chemotherapy with carboplatin paclitaxel was administered for 2 or 3 courses before cytoreductive surgery.
Salinaro et al., 2020 [17]	Neoadjuvant chemotherapy (details were unavailable).